Sign in
Not yet taking people in CzechiaPhase 2

Lower Versus Standard Blood Thinner Doses During ECMO for Heart or Lung Failure

Compares lower and standard doses of argatroban or enoxaparin in adults on ECMO.

Key facts

Who runs it
Fakultni Nemocnice Ostrava
Where
Ostrava and Prague, CzechiaSee the 2 sites
Registry title
Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-IIa or anti-Xa assay
Status
Not yet recruiting
Phase
Phase 2
People taking part
200 people, planned
Started
2 Mar 2026
Expected to end
29 Feb 2028
Type of study
Interventional
Record updated
19 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who are on ECMO (a machine that supports the heart and lungs) and receive argatroban or enoxaparin to prevent blood clots.

Age
18 years or older
Sex
Women and men can join.
Earlier treatment
People must be on ECMO support with argatroban or enoxaparin anticoagulation.

Main reasons for not taking part

  • Included in the lung transplant program at Motol Hospital
  • Known hypersensitivity to components of the investigational medicinal products
  • Allergic reaction to the active substances of the investigational medicinal products
  • Pregnancy
  • Breastfeeding

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • ECMO support with argatroban / enoxaparin anticoagulation
  • Age ≥ 18 years
  • Obtaining informed consent according to the procedure specified in the protocol

Who cannot take part

  • Inclusion in the lung transplant program at Motol Hospital
  • Known hypersensitivity to components of the investigational medicinal products
  • Allergic reaction to the active substances of the investigational medicinal products
  • Pregnancy and breastfeeding

Where in Czechia

  • Fakultni nemocnice OstravaOstrava, CzechiaNot yet recruiting
  • Fakultni nemocnice v MotolePrague, CzechiaNot yet recruiting

About the trial

What the trial wants to find out

Description of the efficacy and safety of low dose (LD) and standard dose (SD) anticoagulation with argatroban and enoxaparin in patients on ECMO support.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-IIa or anti-Xa assay
Plain-language title
Lower Versus Standard Blood Thinner Doses During ECMO for Heart or Lung FailureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
19 March 2026